Experienced in Lung Nodules

Dr. Theodore W. Pollock

Hematology Oncology | Oncology
Northeastern Health System
1400 E Downing St, 
Tahlequah, OK 
 (684.3 mi)
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Experienced in Lung Nodules
Northeastern Health System
1400 E Downing St, 
Tahlequah, OK 
 (684.3 mi)
OverviewInsuranceLocationsClinical Research

Overview

Theodore Pollock is a Hematologist Oncology specialist and an Oncologist in Tahlequah, Oklahoma. Dr. Pollock and is rated as an Experienced provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Anal Cancer, and Familial Colorectal Cancer. Dr. Pollock is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Northeastern Health System
Cherokee Nation W W Hastings Indian Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medica
  •  UnitedHealthcare
  •  Humana

Locations

NORTHEASTERN HEALTH SYSTEM
1400 E Downing St, Tahlequah, OK 74464

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: February 17, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

3 Total Publications

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Journal: JAMA oncology
Published: June 04, 2021
Similar Doctors
Advanced in Lung Nodules
Dr. Daniel S. Bradford
Hematology Oncology
Advanced in Lung Nodules
Dr. Daniel S. Bradford
Hematology Oncology
808 S 52nd St, 
Rogers, AR 
 (51.1 mi)
479-936-9900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Bradford is a Hematologist Oncology provider in Rogers, Arkansas. Dr. Bradford and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Hodgkin Lymphoma, and Classical Hodgkin Lymphoma. Dr. Bradford is currently accepting new patients.

Advanced in Lung Nodules
Dr. Lynsay L. Brautnick
Hematology Oncology | Oncology | Hematology
Advanced in Lung Nodules
Dr. Lynsay L. Brautnick
Hematology Oncology | Oncology | Hematology

Highlands Oncology Group PA

808 S 52nd St, 
Rogers, AR 
 (51.1 mi)
479-936-9900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lynsay Brautnick is a Hematologist Oncology specialist and an Oncologist in Rogers, Arkansas. Dr. Brautnick and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. Her top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Familial Pancreatic Cancer, Virilizing Ovarian Tumor, and Ureteroscopy. Dr. Brautnick is currently accepting new patients.

Advanced in Lung Nodules
Dr. Eric S. Schaefer
Hematology Oncology | Oncology | Hematology
Advanced in Lung Nodules
Dr. Eric S. Schaefer
Hematology Oncology | Oncology | Hematology

Highlands Oncology Group PA

3232 N Northhills Blvd, Highlands Oncology Grp Partnership, 
Fayetteville, AR 
 (46.3 mi)
479-587-1700
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Schaefer is a Hematologist Oncology specialist and an Oncologist in Fayetteville, Arkansas. Dr. Schaefer and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, Gastrostomy, and Endoscopy. Dr. Schaefer is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile